Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on brain-targeted therapeutics, has provided key updates on its Phase IIa feasibility trial of ONP-002 for mild traumatic brain injury (mTBI), its U.S. regulatory pathway, and its NYSE American listing status. The company has dosed nine participants across three active Australian clinical sites: Alfred Health, Mackay, and Royal Adelaide Hospital. These sites are part of the ongoing trial evaluating ONP-002, a potential first-in-class intranasal treatment for concussion and mTBI.
In regulatory developments, Oragenics has received responses from the U.S. Food and Drug Administration (FDA) regarding its Type B meeting request briefing package submitted in July 2026. The company is currently reviewing the FDA responses and remains focused on submitting an Investigational New Drug (IND) application by the end of 2026. This step is crucial for advancing ONP-002 into U.S. clinical trials, with Phase 2b trials planned to follow the Australian studies.
However, Oragenics also disclosed a challenge with its exchange listing. On Aug. 26, 2026, the company received a deficiency letter from NYSE American regarding stockholders' equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The company has 45 days from receipt of the letter to submit a plan to regain compliance and intends to do so within the required timeframe. If the plan is accepted, Oragenics would be able to maintain its listing during a cure period, subject to periodic review, with a compliance deadline of Feb. 25, 2028.
These updates underscore the dual challenges and opportunities facing Oragenics as it progresses its lead candidate. The advancement of the Phase IIa trial in Australia is a positive step toward validating ONP-002's efficacy and safety in mTBI patients. The FDA's responses to the briefing package will inform the company's regulatory strategy, potentially accelerating the path to U.S. trials. However, the NYSE American listing issue highlights the financial hurdles that clinical-stage biotech companies often face, as they must balance research and development costs with maintaining exchange compliance.
The mTBI market represents a significant unmet medical need, with no FDA-approved treatments specifically for concussion. If ONP-002 proves successful, it could become a first-in-class therapy, offering hope to millions of patients worldwide. Oragenics' proprietary intranasal delivery platform also has potential applications in other neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders, which could expand its therapeutic reach.
Investors and stakeholders will be watching closely as Oragenics navigates these regulatory and financial milestones. The company's ability to submit a compelling IND and maintain its NYSE American listing will be critical in the coming months. For more information, visit the company's newsroom at https://nnw.fm/OGEN.
